Shane Barton - 25 Sep 2024 Form 3 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Principal Accounting Officer
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Issuer symbol
BIOA
Transactions as of
25 Sep 2024
Net transactions value
$0
Form type
3
Filing time
25 Sep 2024, 16:43:18 UTC
Previous filing
09 Jun 2023
Next filing
10 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIOA Stock Option (Right to Buy) 25 Sep 2024 Common Stock 26,890 $10.85 Direct F1
holding BIOA Stock Option (Right to Buy) 25 Sep 2024 Common Stock 28,277 $8.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as to 1/4th of the total award on September 25, 2024, and thereafter shall vest as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.